RISPERIDONE DEPOT vs OLANZAPINE
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
- no estimate extracted1 study · 361 participantsLow
Findings
What do systematic reviews say?
105 questions · 106 findings · 16 reviews · Schizophrenia
No studies found 20 · 18.9%GRADE not reported 7 · 6.6%Very low 40 · 37.7%Low 23 · 21.7%Moderate 9 · 8.5%High 7 · 6.6%
RISPERIDONE DEPOT vs OLANZAPINE
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
- RR 1.32 [1.1, 1.58]1 study · 618 participantsLow
RISPERIDONE DEPOT vs OLANZAPINE
Adverse events: General ‐ serious · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
- RR 1.1 [0.8, 1.51]1 study · 547 participantsLow
RISPERIDONE DEPOT vs OLANZAPINE
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
- RR 1.67 [1.19, 2.36]1 study · 547 participantsLow
RISPERIDONE DEPOT vs OLANZAPINE
Weight gain · patients with schizophrenia
RISPERIDONE DEPOT may leads to lower adverse events: Specific ‐ weight increase compared with ORAL OLANZAPINE (low certainty).
1 finding from 1 review
- RR 0.56 [0.42, 0.75]1 study · 547 participantsLow
HALOPERIDOL + PROMETHAZINE vs OLANZAPINE
Adverse effects: Specific and serious adverse effect ‐ by 24 hours Central nervous system ‐ excessive sedation · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in adverse effects: Specific and serious adverse effects by 24 hours… compared with ANTIPSYCHOTIC ‐ OLANZAPINE (low certainty).
1 finding from 1 review
- Haloperidol plus promethazine for psychosis‐induced aggression 2016 · Cochrane Headline outcomes onlyRR 0.67 [0.12, 3.84]2 studies · 116 participantsLow
HALOPERIDOL + PROMETHAZINE vs OLANZAPINE
Adverse effect: Specific ‐ Death · people with psychosis‐induced aggression
1 finding from 1 review
- Haloperidol plus promethazine for psychosis‐induced aggression 2016 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
HALOPERIDOL + PROMETHAZINE vs OLANZAPINE
Service outcomes: Not discharged ‐ by 4 hours · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in service outcomes: Not discharged ‐ by 4 hours compared with ANTIPSYCHOTIC ‐ OLANZAPINE (high certainty).
1 finding from 1 review
- Haloperidol plus promethazine for psychosis‐induced aggression 2016 · Cochrane Headline outcomes onlyRR 0.94 [0.77, 1.16]1 study · 300 participantsHigh
HALOPERIDOL + PROMETHAZINE vs OLANZAPINE
Aggression · people with psychosis‐induced aggression
1 finding from 1 review
- Haloperidol plus promethazine for psychosis‐induced aggression 2016 · Cochrane Headline outcomes onlyno estimate extracted1 study · 60 participantsLow
HALOPERIDOL + PROMETHAZINE vs OLANZAPINE
Economic outcomes: Cost of care · people with psychosis‐induced aggression
1 finding from 1 review
- Haloperidol plus promethazine for psychosis‐induced aggression 2016 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 0 participantsGRADE not reported
HALOPERIDOL + PROMETHAZINE vs OLANZAPINE
Tranquil or asleep: Not tranquil or asleep ‐ by 30 mins · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in tranquil or asleep: Not tranquil or asleep ‐ by 30 mins compared with ANTIPSYCHOTIC ‐ OLANZAPINE (high certainty).
1 finding from 1 review
- Haloperidol plus promethazine for psychosis‐induced aggression 2016 · Cochrane Headline outcomes onlyRR 0.6 [0.22, 1.61]1 study · 300 participantsHigh
HALOPERIDOL + PROMETHAZINE vs OLANZAPINE
Global state: Needing restraints or seclusion ‐ by 12 hours · people with psychosis‐induced aggression
HALOPERIDOL + PROMETHAZINE showed no clear difference in global state: Needing restraints or seclusion by 12 hours compared with ANTIPSYCHOTIC ‐ OLANZAPINE (low certainty).
1 finding from 1 review
- Haloperidol plus promethazine for psychosis‐induced aggression 2016 · Cochrane Headline outcomes onlyRR 5 [0.62, 40.28]1 study · 60 participantsLow
CHLORPROMAZINE vs OLANZAPINE
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
CHLORPROMAZINE may leads to higher no significant clinical response: short term (up to 6 months) compared with OLANZAPINE (low certainty).
1 finding from 1 review
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes onlyRR 2.34 [1.37, 3.99]3 studies · 204 participantsLow
CHLORPROMAZINE vs OLANZAPINE
Relapse · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes relapse: long term (over 12 months) compared with OLANZAPINE (very low certainty).
1 finding from 1 review
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes onlyRR 1.5 [0.46, 4.86]1 study · 70 participantsVery low
CHLORPROMAZINE vs OLANZAPINE
Mental state: General ‐ average endpoint score (BPRS, high score = poor) ‐ medium term ( · patients with schizophrenia
1 finding from 1 review
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 245 participantsVery low
CHLORPROMAZINE vs OLANZAPINE
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes adverse effects: any observed extrapyramidal symptoms ‐ short term… compared with OLANZAPINE (very low certainty).
1 finding from 1 review
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes onlyRR 34.47 [4.79, 248.3]2 studies · 298 participantsVery low
CHLORPROMAZINE vs OLANZAPINE
Health‐related quality of life (physical) · patients with schizophrenia
1 finding from 1 review
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes onlyno estimate extracted1 study · 61 participantsVery low
CHLORPROMAZINE vs OLANZAPINE
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to any reason: short term (up to 6 months) compared with OLANZAPINE (very low certainty).
1 finding from 1 review
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes onlyRR 1.69 [0.45, 6.4]3 studies · 139 participantsVery low
FLUPHENAZINE (ORAL) vs OLANZAPINE
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of PANSS score < 40%, decreased rate of BPRS score < 40% · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with OLANZAPINE (very low certainty).
1 finding from 1 review
- Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes onlyRR 1.33 [0.86, 2.07]1 study · 60 participantsVery low
FLUPHENAZINE (ORAL) vs OLANZAPINE
Relapse ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found